Download - Three key messages on tuberculosis control
![Page 1: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/1.jpg)
Three key messages on tuberculosis control
World Tuberculosis Day 2010
ECDC TB TeamEuropean Centre for Disease Prevention and ControlStockholm, 24 March 2010
![Page 2: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/2.jpg)
Message 1The treatment success rate in the EU/EEA is too low to meet global targets
![Page 3: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/3.jpg)
1a. The treatment success rate in the EU/EEA is too low to meet global targetsReported treatment success rates in the EU/EEA are far below the 85% target set by the WHO World Health Assembly. Only three EU/EEA countries recorded a treatment success rate over 85% or more for new laboratory-confirmed pulmonary TB cases.
* Treatment success rate among not previously diagnosed cases. Source: ECDC
85% target set by the Stop TB Partnership.Only Iceland, Portugal and Slovakia meet the 85% target.
Figure 1a: Treatment success rate among new laboratory-confirmed pulmonary TB cases, 2007
0102030405060708090
100
% T
reat
men
t suc
cess
rate
![Page 4: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/4.jpg)
1b. The treatment success rate in the EU/EEA is too low to meet global targetsFigure 1b: Percentage success rate among laboratory-confirmed new pulmonary TB cases, EU/EEA, 2007
71 to 84%
≥ 85%
60 to 70%
< 60%
Not included or not reporting
Source: ECDC
![Page 5: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/5.jpg)
1c. The treatment success rate in the EU/EEA is too low to meet global targetsTreatment success among previously untreated laboratory-confirmed pulmonary TB remains low in the EU/EEA and is below the 85% target. No changes in the trend were seen in the last five years. Figure 1c: EU/EEA treatment outcome among laboratory-confirmed pulmonary cases 2003–2007
0.0010.0020.0030.0040.0050.0060.0070.0080.0090.00
100.00
2003 2004 2005 2006 2007 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007* Excluded: Austria, Bulgaria, Finland, France, Greece, Liechtenstein, Luxembourg, and Spain
Previously untreated Previously treated All pulmonary cases
Success
Died
Failed
Defaulted
Still on treatment
Transferred or unknown
* Excluded: Austria, Bulgaria, Cyprus, Finland, France, Greece, Italy, Liechtenstein and Spain
1009080706050403020100
![Page 6: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/6.jpg)
Message 2Multidrug-resistant tuberculosis (MDR TB) remains a problem in the EU/EEA
![Page 7: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/7.jpg)
2a. MDR TB* remains a problem in the EU/EEAFigure 2a: Proportion of notified TB cases with primary multidrug resistance, EU/EEA, 2008
2 to 5.9%
> 10%
1 to 1.9%
> 6-10%
< 1%
Not included or not reporting
* Multidrug-resistant tuberculosis (MDR TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP), the two most powerful first-line anti-TB drugs.
![Page 8: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/8.jpg)
2b. MDR TB remains a problem in the EU/EEA Treatment success rate among MDR TB cases is extremely low (31%).
78%
31%
7%
17%
3%
17%
6%13%
2%
17%
5% 5%0
10
20
30
40
50
60
70
80
90
MDR MDR MDR MDR MDR MDR
Success Died Failed Defaulted Still on treatment
Transferred or unknown
Figure 2b: Treatment outcome of all* MDR TB cases, compared to all non-MDR cases, EU/EEA, 2006**
* Pulmonary and extra-pulmonary ** Both groups are 2006 treatment cohorts
Non-MDR Non-MDR Non-MDR Non-MDR Non-MDRNon-MDR
![Page 9: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/9.jpg)
Message 3The decline in tuberculosis has levelled off in the EU/EEA
![Page 10: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/10.jpg)
3a. The decline in tuberculosis has levelled off in the EU/EEA
Figure 3a: TB notification rates by incidence grouping, 1995–2008 and 2002–2008
Source: ECDC
The decrease in TB notification rates has stagnated in the EU/EEA.The decline seen in countries with high and intermediate incidence rates contributes substantially to the average EU/EEA decline.
<20/100 000
EU/EEA
>20/100 000
Notifi
catio
n ra
te (p
er 1
00 0
00 p
opul
atio
n)
![Page 11: Three key messages on tuberculosis control](https://reader036.vdocument.in/reader036/viewer/2022062315/568161e5550346895dd20384/html5/thumbnails/11.jpg)
3b. The decline in tuberculosis has levelled off in the EU/EEA
0
5
10
15
20
25
19951996199719981999200020012002200320042005200620072008
19951996
19971998
1999
200025
20
15
10
5
0
20012002
20032004
20052006
20072008
Notification rate (per 100 000 population)
Figure 3b: TB notification rates, 1995–2008, EU/EEA